Skip to main content

Table 2 Change from baseline in quality of life measures and number of monthly migraine headache days with acute medication use at Month 3a

From: Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study

Parameter

Total population

CM

EM

 

Placebo

GMB 120 mg

Placebo

GMB 120 mg

Placebo

GMB 120 mg

MSQ total score

n = 84

n = 94

n = 41

n = 40

n = 43

n = 54

Change from baseline, mean (SE)

11.6 (2.6)

26.0 (2.5)

5.7 (3.1)

24.4 (3.4)

13.6 (3.4)

22.1 (3.2)

Difference, mean (SE)

14.4 (2.8)

18.7 (3.9)

8.5 (3.8)

P

<.0001

<.0001

0.0267

MSQ role function restrictive

n = 84

n = 94

n = 41

n = 40

n = 43

n = 54

Change from baseline, mean (SE)

12.0 (2.8)

27.3 (2.7)

4.7 (3.4)

25.2 (3.6)

14.5 (3.6)

22.7 (3.4)

Difference, mean (SE)

15.3 (3.0)

20.5 (4.2)

8.2 (4.0)

P

<.0001

<.0001

0.0426

MSQ role function emotional

n = 84

n = 94

n = 41

n = 40

n = 43

n = 54

Change from baseline, mean (SE)

14.5 (3.2)

28.9 (3.1)

9.2 (4.0)

28.3 (4.4)

14.7 (4.1)

24.2 (4.0)

Difference, mean (SE)

14.4 (3.4)

19.0 (5.0)

9.5 (4.7)

P

<.0001

0.0003

 

0.0479

 

MSQ role function preventive

n = 84

n = 94

n = 41

n = 40

n = 43

n = 54

Change from baseline, mean (SE)

8.8 (2.5)

21.4 (2.4)

3.5 (3.1)

18.7 (3.3)

10.9 (3.2)

19.2 (3.0)

Difference, mean (SE)

12.6 (2.6)

15.2 (3.8)

8.3 (3.6)

P

<.0001

.0001

.0233

Migraine Disability Assessment total score

n = 85

n = 95

n = 42

n = 40

n = 43

n = 55

Change from baseline, mean (SE)

−2.5 (6.6)

−28.2 (6.5)

8.9 (10.5)

−31.0 (11.8)

−8.0 (5.4)

−18.2 (5.2)

Difference

   

P

.0001

.0026

.084

Number of monthly migraine headache days with acute medication use

n = 86

n = 98

n = 42

n = 42

n = 44

n = 56

Change from baseline, mean (SE)

−0.7 (0.7)

−5.3 (0.7)

−0.8 (1.0)

−7.0 (1.1)

−0.7 (0.8)

−3.5 (0.7)

Difference, mean (SE)

−4.6 (0.7)

−6.2 (1.8)

−2.8 (0.8)

P

<.0001

<.0001

.0008

  1. CM Chronic migraine, EM Episodic migraine, MSQ Migraine-specific quality of life questionnaire, SE Standard error
  2. a Patients who had failed 3–4 preventive medication categories due to inadequate efficacy (after at least 2 months at maximum tolerated dose), or safety or tolerability reasons within the last 10 years